Stock Analysis, Dividends, Split History

LJPC / La Jolla Pharmaceutical Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price22.07
Volume277,300.00
Market Cap ($M)531.34
Enterprise Value ($M)289.94
Book Value ($M)115.67
Book Value / Share4.41
Price / Book4.59
NCAV ($M)90.55
NCAV / Share3.45
Price / NCAV5.87
Share Statistics
Common Shares Outstanding 22,168,242
Common Stock Shares Outstanding 22,167,529
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.30
Return on Assets (ROA)-1.62
Return on Equity (ROE)-1.88
Balance Sheet (mrq) ($M)
Assets273.14
Liabilities157.47
Quick Ratio13.00
Current Ratio13.05
Income Statement (mra) ($M)
Revenue From Related Parties0.00
Revenues0.00
Operating Income-115.43
Net Income-114.80
Earnings Per Share Basic And Diluted-5.41
Cash Flow Statement (mra) ($M)
Cash From Operations-84.88
Cash from Investing-9.19
Cash from Financing-9.19
Identifiers and Descriptors
CUSIP503459604
Central Index Key (CIK)920465
Related CUSIPS
503459954 503459904

Split History

Stock splits are used by La Jolla Pharmaceutical Co. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Stocks To Watch: Time To Talk Valuation

2018-09-01 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (298-8)

7 Biotech Stocks Insiders Are Loading Up On

2018-08-22 247wallst
Biotechnology stocks have a reputation for being some of the most speculative, most volatile stocks out there. Investors and would-be investors have to stay alert to avoid getting burned. One encouraging sign in any company is when insiders put their money where their mouth is and buy shares. Lately, some insiders at biotech companies have been doing just that, sometimes taking advantage of share price moves (not to mention buy windows opening up) in the wake of the release of quarterly reports. (24-11)

La Jolla Pharmaceutical Co (LJPC) CEO George Tidmarsh on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
La Jolla Pharmaceutical Co (NASDAQ:LJPC) Q2 2018 Earnings Conference Call August 8, 2018 4:30 PM ET

Galectin Therapeutics IPF Patent Solidifies Platform Technology Status

2018-07-05 seekingalpha
Galectin Therapeutics (NASDAQ:GALT) announced on June 27th its patent for the method and treatment of Idiopathic Pulmonary Fibrosis (NYSEARCA:IPF). The significance of this patent was initially received as extremely positive by the market, but recent structural pressures like the option exercise of a key departing officer continued to weigh on the price. Based on the recent Form 4 Filings, the selling pressure has abated because the officers have simply run out of options to sell. (24-2)

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

CUSIP: 503459604